BOSTON, October 26, 2026--PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory High-Risk Myelodysplastic Syndromes & Acute Myeloid Leukemia (AML) at ESMO 2026
PureTech Health PLC (PTCHF) ended H1 2026 with $220 million in cash, cut go-forward burn to $30--$40 million annually, and is running ahead of its target of three concept-stage programs per year.
PureTech Health (NASDAQ:PRTC) outlined progress across its portfolio in its 2026 half-year results call, highlighting external financings for Celea Therapeutics and Seaport Therapeutics, regulatory progress at Gallop Oncology, and a strategy centered on earlier external funding for its founded entit
PureTech Health plc (LSE:PRTC) said it will publish its results for the six months ended 30 June 2026 on Tuesday, 22 September 2026. The company will hold a presentation and conference call at 9:00 a.
BOSTON, August 25, 2026--PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
This is the newest page. Registered accounts read further back.